Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study (Q33437481)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study |
scientific article |
Statements
1 reference
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study (English)
1 reference
1 reference
M Catherine Pietanza
1 reference
Todd M Bauer
1 reference
Neal Ready
1 reference
Daniel Morgensztern
1 reference
Bonnie S Glisson
1 reference
Lauren A Byers
1 reference
Melissa L Johnson
1 reference
Howard A Burris
1 reference
Francisco Robert
1 reference
Tae H Han
1 reference
Sheila Bheddah
1 reference
Noah Theiss
1 reference
Sky Watson
1 reference
Deepan Mathur
1 reference
Bharathi Vennapusa
1 reference
Hany Zayed
1 reference
Satwant Lally
1 reference
Donald K Strickland
1 reference
Ramaswamy Govindan
1 reference
Scott J Dylla
1 reference
Stanford L Peng
1 reference
David R Spigel
1 reference
SCRX16-001 investigators
1 reference
2 December 2016
1 reference
1 reference
18
1 reference
1
1 reference
42-51
1 reference
Identifiers
1 reference
1 reference